HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RQ3013 COVID-19 vaccine

a cocktail of mRNAs encoding three structural proteins: spike, membrane, and envelope to form SARS-CoV-2 virus-like particles (VLP)

Also Known As:

RQ3013; RQ3013-VLP

Networked: 2 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	COVID-19 11/14/2023 - "These results provide strong support for the evaluation of RQ3013 in clinical trials and suggest that it may be a promising candidate for broad protection against COVID-19 and its variants." 10/01/2023 - "The heterologous prime-boost regimen with RQ3013 elicited superior immune responses and demonstrated better protection against symptomatic SARS-CoV-2 infections compared with Ad5-nCoV or ZF2001, supporting the use of RQ3013 as a booster vaccination in adults. "
2.	Infections 11/14/2023 - "In mice and NHP, two doses of RQ3013 protected the upper and lower respiratory tract against infection by SARS-CoV-2 and its variants. "

Related Drugs and Biologics

1.	ZF2001 COVID-19 vaccine